Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

1,617 public trials 340 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Active, Not Recruiting

Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

NCT05303792

Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Burkitt Lymphoma, +21 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
View all 72 locations
View Trial Details
Active, Not Recruiting

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

NCT05602194

Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, +26 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Kingman Regional Medical Center Kingman, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 228 locations
View Trial Details
Active, Not Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

NCT04799275

Conditions
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, +30 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 176 locations
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

NCT02180711

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Downey, California, United States
  • Research Site Duarte, California, United States
  • Research Site Fountain Valley, California, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +16 more
Locations
  • The University of Arizona Cancer Center - North Campus /ID# 242219 Tucson, Arizona, United States
  • Yale University School of Medicine /ID# 242089 New Haven, Connecticut, United States
  • Christiana Care Health Service /ID# 242301 Newark, Delaware, United States
  • Tampa General Hospital /ID# 246748 Tampa, Florida, United States
View all 76 locations
View Trial Details
Active, Not Recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

NCT04542824

Conditions
Chronic Disease, Diffuse Large B Cell Lymphoma, Disease Attributes, +25 more
Locations
  • Tohoku University Hoaspital Sendai, Miyagi, Japan
  • Aichi Cancer Center Hospital Aichi, Japan
  • NHO Nagoya Medical Center Aichi, Japan
  • National Cancer Center Hospital East Chiba, Japan
View all 15 locations
View Trial Details
Active, Not Recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

NCT03625037

Conditions
Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Chronic Disease, DLBCL, +26 more
Locations
  • Arizona Mayo Clinic Phoenix, Arizona, United States
  • University of California at San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
View all 85 locations
View Trial Details
Active, Not Recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Community Cancer Institute (CCI) Fresno, California, United States
  • Baptist - MD Anderson Cancer Center Jacksonville, Florida, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
View all 63 locations
View Trial Details
Active, Not Recruiting

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

NCT03681535

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital Weymouth, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details

Related conditions